Essentials for selecting antimicrobial therapy for intra-abdominal infections

Drugs

Volumn 72, Issue 6, 2012, Pages

  Blot, Stijn ^a   De Waele, Jan J ^a   Vogelaers, Dirk ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Aminoglycosides; Amoxicillinclavulanic acid; Carbapenems; Cephalosporins; Daptomycin; Doripenem; Fluoroquinolones; Glycopeptides; Imidazoles; Imipenemcilastatin; Intra abdominal infections; Linezolid; Meropenem; Moxifloxacin; Piperacillintazobactam; Quinupristindalfopristin; Tigecycline

Indexed keywords

ANTIBIOTIC AGENT; DORIPENEM; MOXIFLOXACIN; TIGECYCLINE;

ABDOMINAL INFECTION; ARTICLE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; HUMAN; LOADING DRUG DOSE; PERITONITIS; RISK FACTOR; TREATMENT DURATION;

ANTI-INFECTIVE AGENTS; HUMANS; INTRAABDOMINAL INFECTIONS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

CANDIDA; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 84859894401     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11599800-000000000-00000     Document Type: Article

References (80)

1. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005; 65 (12): 1611-20 (Pubitemid 41138984)
2. Schein M, Marshall J. Source control for surgical infections. World J Surg 2004; 28: 638-45 (Pubitemid 39097117)
3. Singh R, Kumar N, Bhattacharya A, et al. Preoperative predictors of mortality in adult patients with perforation peritonitis. Indian J Crit Care Med 2011; 15 (3): 157-63
4. De Waele JJ. Early source control in sepsis. Langenbecks Arch Surg 2010; 395 (5): 489-94
5. Schein M, Marshall J. Source control: a guide to the management of surgical infections. Heidelberg: Springer Verlag, 2002
6. Evans HL, Raymond DP, Pelletier SJ, et al. Diagnosis of intra-abdominal infection in the critically ill patient. Curr Opin Crit Care 2001; 7: 117-21 (Pubitemid 32411400)
7. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9
8. Chromik AM, Meiser A, Holling J, et al. Identification of patients at risk for development of tertiary peritonitis on a surgical intensive care unit. J Gastrointest Surg 2009; 13 (7): 1358-67
9. Solomkin JS, Hemsell DL, Sweet R, et al. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl. 1: S33-42
10. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29 (Pubitemid 15250137)
11. Berger D, Buttenschoen K. Management of abdominal sepsis. Langenbecks Arch Surg 1998; 383: 35-43 (Pubitemid 28226337)
12. Gauzit R, Pean Y, Barth X, et al. Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: a French prospective observational multicenter study. Surg Infect (Larchmt) 2009; 10: 119-27
13. Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin Microbiol Infect 2009; 15: 224-31
14. Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis 2004; 39: 92-7 (Pubitemid 38879555)
15. Dougherty SH. Antimicrobial culture and susceptibility testing has little value for routinemanagement of secondary bacterial peritonitis. Clin Infect Dis 1997; 25 Suppl. 2: S258-61
16. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30: 536-55 (Pubitemid 38541501)
17. Lawrence PF, Tietjen GW, Gingrich S, et al. Bacteroides bacteremia. Ann Surg 1977; 186: 559-63 (Pubitemid 8215895)
18. De Waele JJ, Hoste EA, Blot SI. Blood stream infections of abdominal origin in the intensive care unit: characteristics and determinants of death. Surg Infect (Larchmt) 2008; 9: 171-7 (Pubitemid 351972570)
19. de Ruiter J, Weel J, Manusama E, et al. The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection 2009; 37: 522-7
20. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763-71 (Pubitemid 47598444)
21. Swenson BR, Metzger R, Hedrick TL, et al. Choosing antibiotics for intra-abdominal infections: what do we mean by "high risk"? Surg Infect (Larchmt) 2009; 10: 29-39
22. Seguin P, Laviolle B, Chanavaz C, et al. Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 2006; 12: 980-5 (Pubitemid 44322570)
23. Vogelaers D, De Bels D, Foret F, et al. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates. A multicentre, observational survey in critically ill patients. Int J Antimicrob Agents 2010; 35: 375-81
24. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 133-64
25. Boyd LB, Atmar RL, Randall GL, et al. Increased fluoroquinolone resistance with time in Escherichia coli from >17 000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect Dis 2008; 8: 4
26. European Centres for Disease Prevention and Control. Surveillance report: antimicrobial resistance surveillance in Europe 2009. Stockholm: European Centres for Disease Prevention and Control, 2009
27. Montravers P, Lepape A, Dubreuil L, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009; 63: 785-94
28. Augustin P, Kermarrec N, Muller-Serieys C, et al. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care 2010; 14: R20
29. Cercenado E, Torroba L, Canton R, et al. Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis. J Clin Microbiol 2010; 48: 456-9
30. Egea P, Lopez-Cerero L, Navarro MD, et al. Assessment of the presence of extended-spectrum beta-lactamase-producing Escherichia coli in eggshells and ready-to-eat products. Eur J Clin Microbiol Infect Dis 2011; 30 (9): 1045-7
31. Dolejska M, Matulova M, Kohoutova L, et al. Extendedspectrum beta-lactamase-producing Escherichia coli in turkey meat production farms in the Czech Republic: national survey reveals widespread isolates with bla(SHV-12) genes on IncFII plasmids. Lett Appl Microbiol 2011; 53: 271-7
32. Jensen VF. The development of antibiotics use in Danish food production [in Danish]. Ugeskr Laeg 2011; 173 (45): 2862-6
33. Hawser SP, Badal RE, Bouchillon SK, et al. Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008. J Med Microbiol 2010; 59: 1050-4
34. Tham J, Odenholt I, Walder M, et al. Extended-spectrum beta-lactamase-producing Escherichia coli in patients with travellers' diarrhoea. Scand J Infect Dis 2010; 42: 275-80
35. Dhanji H, Patel R, Wall R, et al. Variation in the genetic environments of bla(CTX-M-15) in Escherichia coli from the faeces of travellers returning to the United Kingdom. J Antimicrob Chemother 2011; 66: 1005-12
36. Edelsberg J, Berger A, Schell S, et al. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt) 2008; 9: 335-47 (Pubitemid 351873405)
37. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-93
38. Dupont H, Friggeri A, Touzeau J, et al. Enterococci increase the morbidity and mortality associated with severe intraabdominal infections in elderly patients hospitalized in the intensive care unit. J Antimicrob Chemother 2011; 66: 2379-85
39. Riche FC, Dray X, Laisne MJ, et al. Factors associated with septic shock and mortality in generalized peritonitis: comparison between community-acquired and postoperative peritonitis. Crit Care 2009; 13: R99
40. Seguin P, Brianchon C, Launey Y, et al. Are enterococci playing a role in postoperative peritonitis in critically ill patients? Eur J Clin Microbiol Infect Dis. Epub 2011 Nov 12
41. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000; 232: 254-62 (Pubitemid 30616727)
42. Ohlin B, Cederberg A, Forssell H, et al. Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections. Eur J Surg 1999; 165: 875-84 (Pubitemid 29459710)
43. Walker AP, Nichols RL, Wilson RF, et al. Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 1993; 217: 115-21 (Pubitemid 23059281)
44. Fernandez-Guerrero ML, Herrero L, Bellver M, et al. Nosocomial enterococcal endocarditis: a serious hazard for hospitalized patients with enterococcal bacteraemia. J Intern Med 2002; 252: 510-5 (Pubitemid 35454327)
45. Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002; 46: 1619-28 (Pubitemid 34535173)
46. Harbarth S, Uckay I. Are there patients with peritonitis who require empiric therapy for enterococcus? Eur J Clin Microbiol Infect Dis 2004; 23: 73-7 (Pubitemid 38392132)
47. Patel R, Badley AD, Larson-Keller J, et al. Relevance and risk factors of enterococcal bacteremia following liver transplantation. Transplantation 1996; 61: 1192-7 (Pubitemid 26134769)
48. Swoboda S, Ober M, Hainer C, et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 2008; 61: 729-33 (Pubitemid 351321153)
49. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002; 62: 425-41 (Pubitemid 34211023)
50. Blot S, Vandewoude K. Management of invasive candidiasis in critically ill patients. Drugs 2004; 64 (19): 2159-75 (Pubitemid 39382207)
51. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-72 (Pubitemid 29314312)
52. Rex JH. Candida in the peritoneum: passenger or pathogen? Crit Care Med 2006; 34: 902-3
53. Lee SC, Fung CP, Chen HY, et al. Candida peritonitis due to peptic ulcer perforation: incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B. Diagn Microbiol Infect Dis 2002; 44: 23-7
54. Blot S, Vandewoude K, De Waele J. Candida peritonitis. Curr Opin Crit Care 2007; 13: 195-9 (Pubitemid 46328335)
55. Magill SS, Swoboda SM, Johnson EA, et al. The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. Diagn Microbiol Infect Dis 2006; 55: 293-301 (Pubitemid 44137494)
56. Agvald-Ohman C, Klingspor L, Hjelmqvist H, et al. Invasive candidiasis in long-term patients at a multidisciplinary intensive care unit: candida colonization index, risk factors, treatment and outcome. Scand J Infect Dis 2008; 40: 145-53
57. Dupont H, Bourichon A, Paugam-Burtz C, et al. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Critical Care Med 2003; 31: 752-7 (Pubitemid 36379578)
58. Blot S, Janssens R, Claeys G, et al. Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother 2006; 58: 474-7 (Pubitemid 44294971)
59. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35
60. Pine RW, Wertz MJ, Lennard ES, et al. Determinants of organ malfunction or death in patients with intraabdominal sepsis: a discriminant analysis. Arch Surg 1983; 118: 242-9 (Pubitemid 13181582)
61. Mulier S, Penninckx F, Verwaest C, et al. Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. World J Surg 2003; 27: 379-84 (Pubitemid 36920106)
62. Schneider CP, Seyboth C, Vilsmaier M, et al. Prognostic factors in critically ill patients suffering from secondary peritonitis: a retrospective, observational, survival time analysis. World J Surg 2009; 33: 34-43
63. Saxon A, Hassner A, Swabb EA, et al. Lack of crossreactivity between aztreonam, a monobactam antibiotic, and penicillin in penicillin-allergic subjects. J Infect Dis 1984; 149: 16-22 (Pubitemid 14179884)
64. Saxon A, Beall GN, Rohr AS, et al. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 1987; 107: 204-15 (Pubitemid 17137856)
65. Barberán J, Mensa J, Fariñ as C, et al. Recommendations of antimicrobial treatment in patients allergic to beta-lactam antibiotics [in Spanish]. Rev Esp Quimioter 2008; 21 (1): 60-82 (Pubitemid 351899648)
66. Bone RC. Let's agree on terminology: definitions of sepsis. Crit Care Med 1991; 19: 973-6
67. Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008; 30: 868-83 (Pubitemid 351799866)
68. Pillar CM, Torres MK, Brown NP, et al. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008; 52: 4388-99
69. Wirtz M, Kleeff J, Swoboda S, et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrobial Chemother 2004; 53: 875-7 (Pubitemid 38660296)
70. Edminston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48: 1012-6 (Pubitemid 38280357)
71. Solomkin J, Zhao Y-P, Ma E-L, et al., DRAGON Study Team. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009; 34: 439-45
72. Malangoni MA, Song J, Herrington J, et al. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244: 204-11 (Pubitemid 44305534)
73. De Waele J, Tellado J, Reimnitz P, et al. Efficacy and safety of moxifloxacin vs. ertapenem in complicated intraabdominal infections: results of the PROMISE study. Abstracts of the 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 10-13 April 2010. P1549
74. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19-36 (Pubitemid 30085483)
75. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl. 5: S354-67 (Pubitemid 41170382)
76. US Food and Drug Administration. FDA drug safety communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections [online]. Available from URL: http://www.fda.gov/Drugs/ DrugSafety/ucm224370.htm [Accessed 2012Mar 8]
77. Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. Br J Surg 1994; 81: 989-91 (Pubitemid 24230091)
78. Snelling CM, Poenaru D, Drover JW. Minimum postoperative antibiotic duration in advanced appendicitis in children: a review. Pediatr Surg Int 2004; 20: 838-45 (Pubitemid 40202645)
79. Basoli A, Chirletti P, Cirino E, et al. A prospective, doubleblind, multicenter, randomized trial comparing ertapenem 3 vs >or=5 days in community-acquired intraabdominal infection. J Gastrointest Surg 2008; 12 (3): 592-600
80. Laterre PF, Colardyn F, Delmee M, et al. Antimicrobial therapy for intra-abdominal infections: guidelines from the Infectious Diseases Advisory Board. Ghent: Mapu, 2006